Genetic association between <i><scp>VEGF</scp></i> polymorphisms and <scp>BRONJ</scp> in the Korean population

Choi, Hoon Young; Jh, Lee; Kim, Jeehwan

doi:10.1111/odi.12355

Cited by 19 publications

(17 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found that the T allele in the asthma group was present in a significantly higher proportion than in the control group. The VEGF rs3025039 SNP is not only associated with asthma (Lachheb et al, 2008); like the VEGF rs3025020 polymorphism, rs3025039 is also associated with other diseases, for example, bisphosphonate-related osteonecrosis of the jaw (Choi et al, 2015) and ovarian cancers (Janardhan et al, 2015). Compared with healthy controls, the frequency of the T allele of rs3025039 is significantly higher in patients with HCH (He et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

Polymorphisms in the vascular endothelial growth factor (VEGF) gene associated with asthma

Lu¹,

Zhao²,

Fu³

2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. It has been proven that vascular endothelial growth factor (VEGF) is involved in airway restoration and the development of asthma. We sought to examine the relevance of VEGF gene polymorphisms to asthma in the Chinese Han population. We extracted the whole genomic DNA from the peripheral blood of 471 participants, including 226 patients with asthma and 245 healthy controls. Seven single nucleotide polymorphisms (SNPs) of the VEGF gene were genotyped using the MassARRAY system. The data were then analyzed using HaploView 4.0 and SPSS 20.0 softwares. When comparing the asthma and control groups, significant differences were found in the genotype frequencies of rs3025020 and rs3025039 (P = 0.001 and P = 0.011, respectively). The T alleles in rs3025020 and rs3025039 were significantly more prevalent in the asthma group than in controls (P = 0.0003, P = 0.001, respectively). Furthermore, a strong linkage 2 H.Y. Lu et al.

show abstract

Section: Discussionmentioning

confidence: 99%

Polymorphisms in the vascular endothelial growth factor (VEGF) gene associated with asthma

Lu¹,

Zhao²,

Fu³

2016

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…With reference to genetic factors, Choi et al. [68] concluded that the CC homozygotes of rs2010963 and rs3025039 polymorphisms in the VEGF gene were associated with an increased risk of BRONJ in the Korean population. In Japan, many of the risk factors mentioned above for ARONJ has no published evidence to support their importance.…”

Section: Risk Factors For Aronjmentioning

confidence: 99%

Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries

Taguchi

Shiraki²,

Morrison³

et al. 2017

Osteoporosis and Sarcopenia

View full text Add to dashboard Cite

Bisphosphonate (BP)-associated osteonecrosis of the jaw (ONJ) was first reported in oncology patients in 2003 and subsequently in osteoporosis patients in 2004. Since oral surgical procedures, such as tooth extraction, are also considered one of the major risk factors for ONJ, there is confusion among physicians, dentists, and patients—particularly osteoporosis patients currently taking BPs—regarding the safety of remaining on therapy surrounding these procedures. Many papers about BP-related ONJ (BRONJ) have been published to date. In addition to BRONJ, recent studies have reported an association between ONJ and the antiresorptive therapy denosumab (Dmab; a RANKL-inhibitor). BRONJ and Dmab-related ONJ are together referred to as antiresorptive agent-related ONJ (ARONJ). The pathogenesis of ARONJ still remains unknown. It is forecasted that there will be an increased incidence of patients with osteoporotic fractures and an increased number of prescriptions for antiresorptive agents in Asia in the future. However, prescriptions for antiresorptives for osteoporosis may be restricted in the Asian population as the occurrence of ARONJ may be higher as compared with those in other countries. In this review, we focused on the following topics as it pertains to the Asian osteoporotic population: the oral condition specific for osteoporosis patients; definition, staging, prevalence and incidence of ARONJ; imaging modalities for ARONJ; specific risk factors for ARONJ; prevention strategies for ARONJ, and; cooperation between physicians and dentists in the prevention of ARONJ. Ideally, the Asian Federation of Osteoporosis Societies would cooperate with one another and find more population-specific evidence for the prevention of ARONJ.

show abstract

“…There are a number of theories regarding the pathogenesis of MRONJ, with varying levels of evidence to support the following as contributing factors: osteocyte apoptosis (Roelofs et al, ); osteoclast suppression (Allen & Burr, ); inhibition of blood vessel formation (Santini et al, ); obstruction of the vasculature (Favia, Pilolli, & Maiorano, ); suppression of soft tissue healing (Reid, Bolland, & Grey, ), impaired immunity (Pazianas, ), genetic risk factors (Choi, Lee, Lee, & Kim, ); and infection or inflammation as a result of oral biofilms (Sedghizadeh et al, ). The role of oral health, and in particular dental extractions, has been extensively reported.…”

Section: Introductionmentioning

confidence: 99%

Systemic comorbidities are associated with medication‐related osteonecrosis of the jaws: Case–control study

et al. 2019

View full text Add to dashboard Cite

Objectives Medication‐related osteonecrosis of the jaws (MRONJ) is a serious condition developed in up to 15% of patients who take antiresorptive medications. Its underlying pathogenesis remains unclear. The association between systemic comorbidities and MRONJ was investigated. Subjects and Methods A case–control study was conducted in Brisbane, Australia. Hospital records were used to identify 68 cases of MRONJ between January 2003 and March 2017. Each case was individually matched to three controls (204 in total) according to sex, age, primary disease, and type and duration of antiresorptive therapy. Data on patient demographic, social and clinical characteristics were collected. Systemic comorbidities and medications were quantified as a comorbidity–polypharmacy score (CPS). Associations were investigated using conditional logistic regression. Results The CPS calculated for patients who developed MRONJ (mean ± SD = 20.2 ± 5.1) was significantly higher than for controls (12.9 ± 4.6). Multivariable analysis determined a significant relationship between CPS and the presence of MRONJ (OR = 1.5; 95% CI = 1.3, 1.8, p < 0.001). Conclusions Patients with multiple systemic comorbidities and high levels of polypharmacy were more likely to develop MRONJ. The CPS is a simple and effective tool to quantify the risk of MRONJ attributed to a patient's systemic condition and should be considered in conjunction with the patient's oral health to assess the overall risk of MRONJ.

show abstract

Genetic association between VEGF polymorphisms and BRONJ in the Korean population

Abstract: The CC homozygotes of rs2010963 and rs3025039 polymorphisms in the VEGF gene were associated with an increased risk of BRONJ in the Korean population. Further epidemiological cohort studies with a larger sample size would be required to confirm the suggestive correlations.

Cited by 19 publications

References 24 publications

Polymorphisms in the vascular endothelial growth factor (VEGF) gene associated with asthma

Polymorphisms in the vascular endothelial growth factor (VEGF) gene associated with asthma

Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries

Systemic comorbidities are associated with medication‐related osteonecrosis of the jaws: Case–control study

Contact Info

Product

Resources

About